<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Barrera Aguilar | Activity</title>
	<link>https://www.catswannabecats.com/members/nightred0/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/nightred0/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Barrera Aguilar.</description>
	<lastBuildDate>Mon, 06 Jul 2026 08:03:58 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">9704ea433086a2f8f639d2cff26aaef8</guid>
				<title>Barrera Aguilar posted an update: latin and required GCSF prophylaxis. Gene promoter [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/11815/</link>
				<pubDate>Sun, 01 Jun 2025 08:12:41 -0400</pubDate>

									<content:encoded><![CDATA[<p>latin and required GCSF prophylaxis. Gene promoter methylation pharmacodynamics are optimal with this schedule. Addition of guadecitabine to gemcitabine and cisplatin was tolerable, despite some additional myelosuppression, and warrants further investigation to assess efficacy.The combination of atezolizumab and bevacizumab increases overall&hellip;<span class="activity-read-more" id="activity-read-more-11815"><a href="https://www.catswannabecats.com/activity/p/11815/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ba6dc508bf92bc23a634632fd19e7531</guid>
				<title>Barrera Aguilar posted an update: The objetive of these study is to know the characteristics [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/5307/</link>
				<pubDate>Sat, 31 May 2025 14:43:25 -0400</pubDate>

									<content:encoded><![CDATA[<p>The objetive of these study is to know the characteristics of COVID-19 in patients with uveitis associated with Systemic Autoimmune Disease (SAD) through telematic survey.</p>
<p> Internal Medicine Society and Group of Systemic Autoimmune disease conducted a telematic survey of patients with SAD to learn about the characteristics of COVID-19 in&hellip;<span class="activity-read-more" id="activity-read-more-5307"><a href="https://www.catswannabecats.com/activity/p/5307/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">acdb5c3e8fb97ee1b1d9a873d8b274eb</guid>
				<title>Barrera Aguilar became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/5088/</link>
				<pubDate>Sat, 31 May 2025 14:27:29 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>